Mylan Launches Generic Nordette® 28 Tablets

                 Mylan Launches Generic Nordette® 28 Tablets

PR Newswire

PITTSBURGH, Dec. 28, 2012

PITTSBURGH, Dec. 28, 2012 /PRNewswire/ --Mylan Inc. (Nasdaq: MYL) today
announced that its partner Famy Care Ltd. has received final approval from the
U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug
Application (ANDA) for Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.15
mg/0.03 mg. This product is the generic version of Teva Branded Pharmaceutical
Products' Nordette® 28 Tablets, which are indicated for the prevention of
pregnancy in women who elect to use this product as a method of
contraception.(1) The product will be distributed in the U.S. by Mylan
Pharmaceuticals Inc., and the company is shipping product immediately.

Mylan CEO Heather Bresch commented: "The approval and immediate launch of our
Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.15 mg/0.03 mg, represents
an exciting advance for the women's health care franchise that Mylan is
establishing in partnership with Famy Care Ltd., one of the world's largest
manufacturers of oral contraceptives. Presently, we have 34 oral
contraceptives pending approval with the FDA and expect to receive additional
approvals of these products beginning in next year's first quarter."

Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.15 mg/0.03 mg, had U.S.
sales of approximately $60.4 million for the 12 months ending Sept. 30, 2012,
according to IMS Health.

Currently, Mylan has 185 ANDAs pending FDA approval representing $80.6 billion
in annual sales, according to IMS Health. Thirty-five of these pending ANDAs
are potential first-to-file opportunities, representing $21.2 billion in
annual brand sales, for the 12 months ending June 30, 2012, according to IMS
Health.

Mylan is a global pharmaceutical company committed to setting new standards in
health care. Working together around the world to provide 7 billion people
access to high quality medicine, we innovate to satisfy unmet needs; make
reliability and service a habit, do what's right, not what's easy and impact
the future through passionate global leadership. We offer a growing portfolio
of more than 1,100 generic pharmaceuticals and several brand medications. In
addition, we offer a wide range of antiretroviral therapies, upon which
approximately one-third of HIV/AIDS patients in developing countries depend.
We also operate one of the largest active pharmaceutical ingredient
manufacturers and currently market products in approximately 150 countries and
territories. Our workforce of more than 18,000 people is dedicated to
improving the customer experience and increasing pharmaceutical access to
consumers around the world. But don't take our word for it. See for yourself.
See inside. mylan.com

(1) Cigarette smoking increases the risk of serious cardiovascular side
effects from oral contraceptive use and this risk increases with age. Women
who use oral contraceptives should be advised to not smoke. Consult your
physician prior to beginning oral contraceptive use.

SOURCE Mylan Inc.

Website: http://mylan.com
Contact: media, Nina Devlin, +1-724-514-1968, or investors, Kris King,
+1-724-514-1813, for Mylan Inc.